February 2026 - The iCMLf is seeking collaborators to join the iCMLf Cure Consortium (iC3), a global, multidisciplinary initiative focused on achieving a cure for CML.

Background

Over the past two decades, tyrosine kinase inhibitors have transformed CML into a manageable disease. Yet for most patients, cure remains elusive. Nearly half of those who achieve deep molecular response relapse after stopping therapy, reflecting the persistence of leukemia stem cells and their supportive microenvironment. Lifelong treatment carries clinical, psychological, and economic burdens and remains inaccessible or unsustainable in many parts of the world. A cure, therefore, is not only a scientific goal, but a global equity imperative.

GoldmanPrize medal RGB reduc January 2026 - There is still time to help spotlight excellence in CML research, care, and global access by nominating outstanding individuals for the 2026 iCMLf Prizes.

Each year, these prizes honour visionary scientists, clinicians, and advocates whose lifetime contributions have shaped the global CML landscape. If you have not yet done so, we invite you to submit your nominations for one of the three 2026 iCMLf Prizes:

🥇 The Rowley Prize – For exceptional scientific achievements that have transformed our understanding of CML biology.
🥇 The Goldman Prize – Recognising excellence in advancing clinical practice and improving outcomes for CML patients.
🥇 The iCMLf Prize – Celebrating outstanding efforts to overcome CML treatment challenges in low- and middle-income countries.

Nominations for the 2026 Prizes are closed.

January 2026 - This is a friendly reminder to join us for the ‘CML Highlights of ASH 2025’ webinar, the first iCMLf Conversation of 2026, taking place on:

📅 Tuesday, January 20th, 2026
🕐 14:00 Central European Time (CET)
📍 Live webinar on Zoom (45 mins)

Click here for more information and times in other time zones.

If you have not registered yet, you can secure your place here.
Once registered, you’ll receive your Zoom log-in details via Zoom.

Highlights of the 67^th ASH Annual Meeting on January 20^th at 14.00 CET

December 2025 - Join us for our next iCMLf Conversation on Tuesday, January 20^th 2026 at 14.00 Central European Time where two international experts will review and discuss the most important biological and clinical updates presented during the the 67th ASH Annual Meeting.

Whether you attended the conference or not, this session will summarise biological and clinical highlights and will share the most important takeaways for the CML community.

📅 Date: Tuesday, January 20^th
🕑 Time: 14:00 CET
🖥️ Format: Live webinar on Zoom

December 2025 - Each year, we honour exceptional achievements in CML research and management by recognising lifetime contributions through the three iCMLf Prizes. Since their introduction, these awards have celebrated the work of remarkable scientists, clinicians, and advocates whose leadership, innovation, and dedication have shaped the global CML landscape.

We invite you once again to participate in this tradition by nominating outstanding individuals whose work has transformed our understanding of CML biology, advanced patient management, or improved access to treatment worldwide. Let’s spotlight the visionaries whose contributions continue to inspire the global CML community.

ASH logo December 2025 - We're bringing you highlights from the 67th ASH Annual Meeting with a summary of selected scientific sessions on CML, a prospective study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy.

🌟 Oral Abstract Session: CML clinical & epidemiological - Therapeutic agents to enhance patient outcomes

Chairs: Elisabetta Abruzzese (Rome) - Vivian Oehler (Seattle)
This clinical session presented major advances in novel TKIs, frontline optimisation strategies, real-world outcomes in blast-phase CML, and next-generation approaches to achieving deeper and safer molecular responses. Across six presentations, investigators showcased: promising phase 1 data for TERN-701 and TGRX-678, updated results from a frontline asciminib combination trial, the largest US analysis of blast-phase management, a prospectie study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy.

Collectively, the studies demonstrated:

High efficacy and favourable safety of new agents even in heavily pretreated or T315I-mutated patients,
Asciminib’s expanding role in both frontline combinations and second-line therapy,
The persistent challenge and therapeutic needs of blast-phase CML,
The importance of risk-adapted frontline selection to improve long-term TFR outcomes,
And the feasibility of dose escalation strategies with asciminib to address suboptimal responders.

Our key takeaways from the presentations:

Page 1 of 52

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK